2013 FIRST-HALF SALES
Longjumeau, July 23, 2013
| (in thousands of euros) | H1-2012 published (including SBS) | H1-2012 restated (without SBS) | H1-2013 | % change |
| Sales | 89 361 | 87 506 | 89 044 | + 1,8% |
| including Pharmaceutical Synthesis | 55 364 | 55 360 | 58 077 | + 4,9% |
| including Fine Speciality Chemicals | 33 997 | 32 146 | 30 967 | - 3,7 % |
| (unaudited data) |
For information, the sale of SBS was finalised on March 20, 2013. SBS was presented on a specific line as "Net Result on discontinued operation" as of December 31, 2012.
For the first half of 2013, the consolidated sales of the PCAS Group are up by 1.8% compared to the same period of the preceding year, without SBS.
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business has been continuing to develop in 2013 with growth of 4.9% relative to 2012.
Fine Specialty Chemicals
For the first half of 2013, Fine Specialty Chemicals are down (-3.7%) on 2012, affected by a sharp downturn in New Technologies business, while the Performance Chemicals business and, to a lesser extent, the Fragrance-Flavors-Cosmetics business have continued to grow.
The full six-monthly consolidated accounts will be examined by the Board of Directors on September 4, 2013.
About PCAS:
Financial communication : Vincent Touraille - Eric Financial communication : Vincent Touraille - Eric Moissenot | Tel +33 (0)1 69 09 77 85 | www.pcas.com
